Here’s why the Orthocell (ASX:OCC) share price is on the move today

The company has taken another step in getting one of its star products internationally patented.

| More on:
medical doctor performing surgery using surgical instruments

Image source: Getty Images

The Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it’s at 57.5 cents, up by 1.77%, settling back after jumping 4% in early trading.

Let’s have a look at the latest announcement from the regenerative medicine company.

What announcement did Orthocell make?

The Orthocell share price is moving higher after the company announced China and New Zealand have granted patents for its CelGro collagen medical device platform.

Australia and Japan have already granted patents for CelGro. Orthocell also said its patent applications were progressing in the United States and the European Union.

CelGro is a suture-less repair process used to regenerate soft tissue, meaning no potentially damaging stitches are needed. According to the statement, the process can improve the outcomes of surgeries by reducing surgery time, simplifying the techniques, and lessening the risk of additional trauma caused by stitches.

Orthocell reported preclinical studies indicate CelGro provides improved nerve repair and return of muscle function in patients with severed peripheral nerves compared to using sutures.

Orthocell’s managing director, Paul Anderson, commented on the new patents:

These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair.

Sutureless or tensionless repair is of particular importance in the optimal repair of damaged nerves and is a key part of the repair process undertaken in the CelGro nerve regeneration clinical study. This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, EU and AUS.

The CelGro patents are set to expire on 12 October 2035.

Orthocell share price snapshot

Orthocell is currently trading at 57.5 cents per share. That puts Orthocell shares up by 64% over the past 12 months, well surpassing the 27% gains posted by the All Ordinaries Index (ASX: XAO).

Year-to-date, the Orthocell share price has continued to outperform, up 26% so far in 2021.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares